• Engineered Microneedle Patch Restores Mitochondrial Function

  2026-08-06

  This study introduces an annular sector-shaped microneedle patch for targeted delivery of a gene therapy formulation and nicotinamide directly to the trabecular meshwork in glaucoma. The combined approach effectively restores mitochondrial function and lowers intraocular pressure, marking a substantial advance in functional genomics-enabled ocular therapy.

• Flubendazole: Autophagy Modulation in Advanced Cancer Resear

  2026-08-05

  Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) stands out as a DMSO-soluble autophagy activator for precise, reproducible modulation of cell degradation pathways. This article delivers actionable workflows, troubleshooting insights, and evidence-backed protocol enhancements for leveraging Flubendazole in cancer and neurodegenerative disease models.

• Dual Mechanisms of SN-38: FUBP1 Inhibition in Cancer Models

  2026-08-05

  The reference study uncovers that camptothecin and its analog SN-38, beyond their classical role as topoisomerase I inhibitors, directly disrupt the binding of the oncoprotein FUBP1 to its DNA target FUSE. This dual-action mechanism introduces new molecular targets for advanced cancer research and suggests translational potential in tumors with high FUBP1 expression.

• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity i

  2026-08-04

  This study demonstrates that MDM1 overexpression increases p53 expression and apoptosis in colorectal cancer (CRC) cells, significantly enhancing their sensitivity to chemoradiotherapy. These findings position MDM1 as a promising predictive biomarker and mechanistic target for overcoming therapeutic resistance in CRC.

• Purification and Characterization of FANCJ G4 Resolvase Acti

  2026-08-04

  This study details the purification and biochemical characterization of the human DNA helicase FANCJ, focusing on its ability to resolve G-quadruplex (G4) DNA structures. The findings clarify FANCJ's mechanistic roles in genomic stability and DNA repair, providing a foundation for future research on helicase-targeted interventions.

• Dehydroabietic Acid: Dual PPAR-α/γ Agonist for Metabolic Ass

  2026-08-03

  Dehydroabietic acid empowers metabolic disorder research by offering robust dual PPAR-α/γ agonism, enabling precise regulation of lipid metabolism and insulin sensitivity. Unlock advanced workflows and troubleshooting insights for reproducible results with high-purity Dehydroabietic acid from APExBIO.

• GLI Inhibition Reimagined: GANT61 and the Next Era in Cancer

  2026-08-03

  Explore how GANT61, a selective GLI inhibitor, is reshaping translational cancer research by targeting not only tumor growth but also the immune evasion mechanisms that underpin resistance to immunotherapy. This thought-leadership article synthesizes mechanistic insights from recent landmark studies to provide strategic guidance for researchers pursuing next-generation combination regimens.

• Live-Dead Cell Staining Kit: Enabling Next-Gen Localized Ass

  2026-08-02

  Explore how the Live-Dead Cell Staining Kit delivers unprecedented precision in cell viability assessment, with unique insights on optimizing assays for advanced drug delivery and biomaterial models. Learn why Calcein-AM Propidium Iodide staining is pivotal for translational research.

• Promethazine HCl: Applied Workflows for Host-Directed Immuno

  2026-08-01

  Promethazine HCl empowers researchers to dissect histaminergic signaling and macrophage antibacterial mechanisms through robust, reproducible workflows. Its unique dual action—H1 receptor antagonism and ROS/autophagy induction—positions it as an indispensable reagent for inflammation and neuroscience research.

• MK-0812 (A3611): Reliable CCR2 Inhibition for Monocyte Studi

  2026-07-31

  This article addresses critical lab challenges in monocyte trafficking and inflammation research, showcasing how MK-0812 (SKU A3611) delivers reproducible, high-sensitivity CCR2 antagonism. Practical Q&A scenarios illustrate evidence-based workflow optimization, data interpretation, and vendor selection, ensuring researchers can confidently apply MK-0812 in translational and preclinical models.

• Hypoxia-Driven S100A10 Promotes Glioblastoma Growth and Resi

  2026-07-31

  This study identifies S100A10 as a hypoxia-induced driver of glioblastoma proliferation and chemoresistance through PI3K-AKT pathway activation. The findings reveal novel mechanistic insight into tumor adaptation under hypoxia and highlight advanced cell proliferation assays essential for translational research.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Solubility Guide

  2026-07-30

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those with aromatic or phenyl groups—by forming inclusion complexes that enhance aqueous solubility. Its validated use is as a solubility enhancer or drug formulation excipient in pharmaceutical and biochemical workflows. Applications outside these contexts are not supported by current product documentation.

• BMS-345541 Hydrochloride: Precision IKK Inhibitor Workflows

  2026-07-30

  BMS-345541 hydrochloride stands out as a selective IKK inhibitor, enabling nuanced dissection of NF-κB signaling in inflammation and cancer biology research. This article details optimized experimental workflows, troubleshooting strategies, and cutting-edge applications that leverage its unique properties for high-impact bench research.

• Caspofungin (SKU B4972): Streamlining Antifungal Research Wo

  2026-07-29

  This article provides a scenario-driven guide to deploying Caspofungin (SKU B4972) for advanced antifungal research, focusing on its role in overcoming challenges like azole resistance and assay reproducibility. Drawing on peer-reviewed evidence and practical lab experience, the content offers actionable advice for biomedical researchers and laboratory scientists evaluating antifungal agents for Candida studies.

• CDK9 Inhibitor (A3294): Technical Use and Protocol Parameter

  2026-07-29

  CDK9 inhibitor (A3294) offers a selective, non-cytotoxic tool for precise inhibition of cyclin dependent kinase 9, supporting research into transcription elongation and HIV-1 propagation inhibition. It is not intended for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions.

17064 records 1/1138 page Next 12345 下5页 Last page